FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016820377> ?p ?o ?g. }

• W2016820377 endingPage "443" @default.
• W2016820377 startingPage "437" @default.
• W2016820377 abstract "The aim of the present study was to compare the potential of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin to achieve their requisite pharmacokinetic/pharmacodynamic (PK/PD) targets against methicillin-resistant Staphylococcus aureus isolates collected from intensive care unit (ICU) settings. Monte Carlo simulations were carried out to simulate the PK/PD indices of the investigated antimicrobials. The probability of target attainment (PTA) was estimated at minimum inhibitory concentration values ranging from 0.03 to 32 μg/mL to define the PK/PD susceptibility breakpoints. The cumulative fraction of response (CFR) was computed using minimum inhibitory concentration data from the Canadian National Intensive Care Unit study. Analysis of the simulation results suggested the breakpoints of 4 μg/mL for ceftobiprole (500 mg/2 h t.i.d.), 0.25 μg/mL for dalbavancin (1000 mg), 0.12 μg/mL for daptomycin (4 mg/kg q.d. and 6 mg/kg q.d.) and tigecycline (50 mg b.i.d.), and 2 μg/mL for linezolid (600 mg b.i.d.) and vancomycin (1 g b.i.d. and 1.5 g b.i.d.). The estimated CFR were 100, 100, 70.6, 88.8, 96.5, 82.4, 89.4, and 98.3% for ceftobiprole, dalbavancin, daptomycin (4 mg/kg/day), daptomycin (6 mg/kg/day), linezolid, tigecycline, vancomycin (1 g b.i.d.) and vancomycin (1.5 g b.i.d.), respectively. In conclusion, ceftobiprole and dalbavancin have the highest probability of achieving their requisite PK/PD targets against methicillin-resistant Staphylococcus aureus isolated from ICU settings. The susceptibility predictions suggested a reduction of the vancomycin breakpoint to 1 μg/mL." @default.
• W2016820377 created "2016-06-24" @default.
• W2016820377 creator A5037482092 @default.
• W2016820377 creator A5042772929 @default.
• W2016820377 creator A5053884536 @default.
• W2016820377 creator A5090227234 @default.
• W2016820377 date "2014-05-20" @default.
• W2016820377 modified "2023-10-01" @default.
• W2016820377 title "Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant<i>Staphylococcus aureus</i>" @default.
• W2016820377 cites W1959537530 @default.
• W2016820377 cites W1966838097 @default.
• W2016820377 cites W1970698892 @default.
• W2016820377 cites W1972470346 @default.
• W2016820377 cites W1975150477 @default.
• W2016820377 cites W1978616397 @default.
• W2016820377 cites W1981930307 @default.
• W2016820377 cites W1983960319 @default.
• W2016820377 cites W1986576619 @default.
• W2016820377 cites W1986968369 @default.
• W2016820377 cites W2014158951 @default.
• W2016820377 cites W2021867174 @default.
• W2016820377 cites W2027253912 @default.
• W2016820377 cites W2029875114 @default.
• W2016820377 cites W2044087791 @default.
• W2016820377 cites W2044368480 @default.
• W2016820377 cites W2053659927 @default.
• W2016820377 cites W2054829690 @default.
• W2016820377 cites W2060675886 @default.
• W2016820377 cites W2070593812 @default.
• W2016820377 cites W2076664566 @default.
• W2016820377 cites W2078273894 @default.
• W2016820377 cites W2082441919 @default.
• W2016820377 cites W2093989241 @default.
• W2016820377 cites W2094217997 @default.
• W2016820377 cites W2097006353 @default.
• W2016820377 cites W2107372728 @default.
• W2016820377 cites W2109915370 @default.
• W2016820377 cites W2111391558 @default.
• W2016820377 cites W2116089057 @default.
• W2016820377 cites W2125177755 @default.
• W2016820377 cites W2127473408 @default.
• W2016820377 cites W2129122463 @default.
• W2016820377 cites W2132927558 @default.
• W2016820377 cites W2133120422 @default.
• W2016820377 cites W2133902131 @default.
• W2016820377 cites W2134463868 @default.
• W2016820377 cites W2135845389 @default.
• W2016820377 cites W2143084812 @default.
• W2016820377 cites W2144258933 @default.
• W2016820377 cites W2144504167 @default.
• W2016820377 cites W2147441308 @default.
• W2016820377 cites W2149026959 @default.
• W2016820377 cites W2151348288 @default.
• W2016820377 cites W2151549662 @default.
• W2016820377 cites W2151623706 @default.
• W2016820377 cites W2156283731 @default.
• W2016820377 cites W2160529501 @default.
• W2016820377 cites W2167558599 @default.
• W2016820377 cites W2167973138 @default.
• W2016820377 cites W2168849436 @default.
• W2016820377 cites W2169673522 @default.
• W2016820377 cites W2170620267 @default.
• W2016820377 cites W2172100866 @default.
• W2016820377 cites W4232734499 @default.
• W2016820377 cites W4254122983 @default.
• W2016820377 cites W4255086015 @default.
• W2016820377 cites W55698963 @default.
• W2016820377 cites W88967424 @default.
• W2016820377 doi "https://doi.org/10.1111/1440-1681.12195" @default.
• W2016820377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24341387" @default.
• W2016820377 hasPublicationYear "2014" @default.
• W2016820377 type Work @default.
• W2016820377 sameAs 2016820377 @default.
• W2016820377 citedByCount "25" @default.
• W2016820377 countsByYear W20168203772014 @default.
• W2016820377 countsByYear W20168203772015 @default.
• W2016820377 countsByYear W20168203772016 @default.
• W2016820377 countsByYear W20168203772017 @default.
• W2016820377 countsByYear W20168203772018 @default.
• W2016820377 countsByYear W20168203772019 @default.
• W2016820377 countsByYear W20168203772020 @default.
• W2016820377 countsByYear W20168203772021 @default.
• W2016820377 countsByYear W20168203772022 @default.
• W2016820377 countsByYear W20168203772023 @default.
• W2016820377 crossrefType "journal-article" @default.
• W2016820377 hasAuthorship W2016820377A5037482092 @default.
• W2016820377 hasAuthorship W2016820377A5042772929 @default.
• W2016820377 hasAuthorship W2016820377A5053884536 @default.
• W2016820377 hasAuthorship W2016820377A5090227234 @default.
• W2016820377 hasConcept C111113717 @default.
• W2016820377 hasConcept C112705442 @default.
• W2016820377 hasConcept C2777027569 @default.
• W2016820377 hasConcept C2777052132 @default.
• W2016820377 hasConcept C2778651397 @default.
• W2016820377 hasConcept C2778980435 @default.
• W2016820377 hasConcept C2779489039 @default.
• W2016820377 hasConcept C2781336494 @default.
• W2016820377 hasConcept C2781414143 @default.

• next